Literature DB >> 16533473

Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma.

Robert de W Marsh1, Thomas George.   

Abstract

The emergence of effective systemic chemotherapy, along with the parallel development of new targeted cell signal inhibitors for pancreatic cancer treatment, has provided impetus for a re-examination of the appropriate use of chemotherapy and radiation therapy in this malignancy. In addition to exciting developments in the treatment of locally advanced and metastatic disease, new data have emerged regarding the efficacy of adjuvant and neoadjuvant therapy when combined with traditional surgical approaches such as a Whipple procedure. This review summarizes the sentinel clinical trials and discoveries that have influenced the development and deployment of scientifically based multidisciplinary care for today's patients, with a particular focus on modern radiation and chemotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16533473     DOI: 10.1007/s11894-006-0006-8

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  77 in total

1.  Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma.

Authors:  M Reni; M G Panucci; A J Ferreri; G Balzano; P Passoni; G M Cattaneo; S Cordio; U Scaglietti; A Zerbi; G L Ceresoli; C Fiorino; R Calandrino; C Staudacher; E Villa; V Di Carlo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

2.  Intraoperative and conformal external-beam radiation therapy in patients with locally advanced pancreatic carcinoma; results from a feasibility phase II study.

Authors:  J Furuse; T Ogino; M Ryu; T Kinoshita; M Konishi; N Kawano; S Ishikura; W Shimizu; R Sekiguchi; N Moriyama; M Iwasaki; M Yoshino
Journal:  Hepatogastroenterology       Date:  2000 Jul-Aug

3.  Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.

Authors:  David Azria; Marc Ychou; William Jacot; Simon Thezenas; Claire Lemanski; Pierre Senesse; Patricia Prost; René Delard; Bruno Masson; Jean-Bernard Dubois
Journal:  Pancreas       Date:  2002-11       Impact factor: 3.327

4.  Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.

Authors:  Vyomesh Patel; Tyler Lahusen; Terence Sy; Edward A Sausville; J Sivio Gutkind; Adrian M Senderowicz
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

5.  Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: a preliminary report.

Authors:  A S DeNittis; M D Stambaugh; P Lang; P E Wallner; R A Lustig; R O Dillman; S E Order
Journal:  Am J Clin Oncol       Date:  1999-08       Impact factor: 2.339

6.  Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma.

Authors:  H M Ceha; G van Tienhoven; D J Gouma; C H Veenhof; C J Schneider; E A Rauws; S S Phoa; D González González
Journal:  Cancer       Date:  2000-12-01       Impact factor: 6.860

7.  Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.

Authors:  M Mohiuddin; W F Regine; J Stevens; F Rosato; D Barbot; W Biermann; R Cantor
Journal:  J Clin Oncol       Date:  1995-11       Impact factor: 44.544

8.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

9.  Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.

Authors:  Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

10.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

View more
  1 in total

1.  Controversies in the management of borderline resectable proximal pancreatic adenocarcinoma with vascular involvement.

Authors:  Olga N Tucker; Mohamed Rela
Journal:  HPB Surg       Date:  2009-03-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.